Pharmaceuticals in China industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values refer to the value generated by market players.
- The Chinese pharmaceuticals market registered revenue of $161 billion in 2023, representing a compound annual growth rate (CAGR) of 8.2% between 2018 and 2023.
- China dominated the Asia-Pacific pharmaceuticals market in 2023, accounting for the largest share of 41.1% in 2023.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in China
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in China
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the China pharmaceuticals market with five year forecasts
Reasons to Buy
- What was the size of the China pharmaceuticals market by value in 2023?
- What will be the size of the China pharmaceuticals market in 2028?
- What factors are affecting the strength of competition in the China pharmaceuticals market?
- How has the market performed over the last five years?
- What are the main segments that make up China's pharmaceuticals market?
Table of Contents
1 Executive Summary
2 Market Overview
3 Market Data
4 Market Segmentation
5 Market Outlook
6 Five Forces Analysis
7 Competitive Landscape
8 Company Profiles
9 Macroeconomic Indicators
10 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CSPC Pharmaceutical Group Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Sinopharm Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd